Medicilon large animal models such as non-human primates, dogs, rabbits, and miniature pigs have shown unique advantages and value in key areas of drug development
With the advent of the era of precision medicine and the deepening understanding of disease mechanisms, large animal models such as non-human primates, dogs, rabbits, and miniature pigs have shown unique advantages and value in key areas of drug development.
Possible colon cancer vaccine target uncovered in bacteria
Higher rates of certain cancers in countries, such as the UK, may be linked to two particular strains of bacteria. Targeting these with treatments or vaccines could help reduce the risk of colorectal, bladder, and prostate cancers.
Newcells Biotech raises additional funding from investors
Newcastle, UK, 5th December 2024: Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, announces it has raised a furt
Strategies for coping with ILD
Interstitial lung disease (ILD) is a chronic and life-limiting lung disease with no curative options which can take a significant emotional toll on sufferers. A diagnosis of ILD comes with feelings of anxiety and uncertainty about the future.
Capacity is the new capability: meeting market demand
At the recent PDA Universe of Prefilled Syringes and Injection Devices conference in Phoenix Arizona, there were many conversations about the manufacturing landscape for drug delivery devices.
FairJourney Biologics appoints Dr. Marc van Dijk as Chief Scientific Officer of Antibody Discovery and Engineering
Appointment of industry expert to drive innovation and excellence in antibody discovery and engineering, to support market demand from global pharma and biotech
evitria Partners with Sapio Sciences to streamline antibody workflow management and reporting
Leading antibody expression service provider implements Sapio’s ELN and Report Builder for advanced sample tracking and data management
Orbit Discovery and Evergreen Theragnostics expand research collaboration to advance targeted therapeutics development
Oxford, UK, and Springfield, NJ, USA, 3rd December 2024: Orbit Discovery, a leading provider of peptide discovery services, and Evergreen Theragnostics, a radiopharmaceutical company at the forefront of precision medicine, today announced an extension to their research
Case Study: Thames Valley and Surrey Secure Data Environment
The Thames Valley and Surrey Secure Data Environment (SDE) case study highlights the collaboration between NHS and System C to enhance data security and accessibility. The SDE integrates data from multiple sources, providing a secure platform for health and care professionals to access and analyse patient information.
Navigating the EU’s General Product Safety Regulations (GPSR)
Webinar on Tuesday, 10 December 2024, from 1:00 PM to 2:30 PM UK Time to help businesses prepare for the General Product Safety Regulation (GPSR) deadline on 13 December 2024.
Drive business success with Best Employers Eastern Region 2025
Best Employers has been changing the face of employee engagement since 2012, by helping organisations get a deeper understanding of their employees through a detailed engagement survey. Personalised results and tailored action plans then help them evolve their workplaces for the better.
Targeting IL-23, Medicilon assists the development of a variety of new drugs for Psoriasis
With people’s in-depth understanding of the inflammatory pathways of psoriasis, biologics continue to develop. From tumor necrosis factor alpha (TNF-α), to IL-17 inhibitors, and then to IL-23 inhibitors, biologics have brought new light to the treatment of psoriasis again. In recent years, the exploration of IL-23 by new drug developers has never stopped. Medicilon Assists IL-23 Monoclonal…
Babraham Research Campus’ £3.15bn life science ecosystem soars
New report reveals how groundbreaking research at the Campus is delivering major gains for UK economic growth and job creation.
Medicilon neural system disease models help our clients advance novel drug development
Medicilon Pharmacodynamics Department can deliver multiple nervous system models based on anti-depressants, anti-Alzheimer's drugs, sedative-hypnotic and anti-anxiety drugs, analgesics, anti-convulsant, anti-Parkinson's drugs, and anti-schizophrenia drugs.
impulse 2025 - the entrepreneurship programme for innovators is now open for applications
impulse is an action-learning programme designed to catalyse the development of high-potential innovation into commercial propositions, guided by experienced entrepreneurs and mentors from the Cambridge innovation cluster.
Tristan backs £300m+ life sciences platform
Tristan Capital Partners’ debt fund has refinanced a £310m prime life science portfolio located across Cambridge and Oxford, Green Street News can reveal.
Centauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives
Funding to support further development of lead programme for a novel therapeutic targeting Gram-negative bacteria including Multi-Drug-Resistant strains Optimisation will also support application of the Alphamer® platform across other therapeutic indicat
Metrion Biosciences appoints Lee Patterson as CEO
Significant CRO C-suite experience expected to drive growth and commercial expansion into global marketsCambridge, UK, 25 November 2024: Metrion Biosciences, the specialist preclinical contract research organisation (CRO) and a leader in ion channe
Guardtech Group hoping to end golden year with more success at SME National Business Awards
Suffolk contamination control experts looking to add Best Enterprising Business prize to epic 2024 awards haul at glitzy Wembley Stadium showpiece on 6 December
Medicilon delivers fast turnaround time to meet your FDA submission deadline for SEND Format Conversion
Medicilon's preclinical pharmacology and toxicology research team is equipped with a professional send format conversion team and has established a send data conversion platform that is fully developed in terms of software, technology, specification and quality, to realize accurate data conversion and provide a good environment for electronic data submission.
Mapping 1.6 million gut cells to find new ways to treat disease
By combining 25 datasets, researchers have created the largest cohesive cell atlas of the human gut and uncovered a new way that stomach cells may play a role in Inflammatory Bowel Disease.
Early skeleton map reveals how bones form in humans
The first ‘blueprint’ of human skeletal development reveals how the skeleton forms, shedding light on the process of arthritis, and highlighting cells involved in conditions that affect skull and bone growth.
Human immune system is ‘ready to go’ long before birth
By creating the first spatial atlas of the developing human thymus, a vital organ that trains immune cells to protect against infections and cancer, scientists have discovered that the foundation for lifelong immunity is established earlier than previously thought.
Shining a light on the life sciences
The OBN Awards struck an optimistic tone as the best of the UK’s life sciences industry was celebrated
